Veeva Expands Market Reach Through Targeted Strategic Partnerships
On the AI front, EVERSANA joined Veeva's partner program in April to co-develop generative AI tools for content creation and customer engagement. Veeva also advanced its regulatory capabilities this year through partnerships with DNAnexus and Accumulus Synergy, making it easier for pharma companies to manage global filings securely and efficiently.
These partnerships are helping Veeva drive faster adoption, deepen customer relationships, and unlock new growth opportunities across clinical research, AI-driven engagement, and regulatory compliance. By teaming up with key players, Veeva is expanding its reach and making its platform more indispensable, strengthening both its competitive edge and long-term revenue potential.
IQVIA Holdings IQV is strengthening its position by expanding into AI-driven solutions across clinical trials and commercialization. In June 2025, the company launched 'AI agents' designed to streamline everything from patient recruitment to trial coordination. It also partnered with NVIDIA in January 2025 to boost its 'Healthcare-grade AI,' enabling automated workflows and advanced analytics across R&D and real-world data platforms.
Oracle ORCL continues to update its life sciences platforms, focusing on automation and cloud-based scalability. In March 2025, Oracle made Argus Safety 25.1 Cloud generally available for new SaaS customers, incorporating enhanced automation and workflow management features for pharmacovigilance and case processing. Earlier, in October 2024, Oracle unveiled its next-generation Electronic Health Record system, built on Oracle Cloud Infrastructure, with AI embedded into care workflows such as documentation and appointment preparation. The company also continues to enhance its Clinical One platform, focusing on unifying trial design, randomization, supply management, and data capture in a single cloud-native environment.
Shares of VEEV have gained 33.5% in the year-to-date period compared with the industry's growth of 8.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.25, above the industry average. VEEV carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for VEEV's fiscal 2026 earnings implies a 15.8% rise from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Oracle Corporation (ORCL) : Free Stock Analysis Report
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE
SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a first-in-human (FIH) clinical study of JSKN022 for the treatment of advanced malignant solid tumors. JSKN022 is an innovative bispecific ADC developed in-house with Alphamab's proprietary glycan-specific conjugation platform. The molecule simultaneously targets and binds to both PD-L1 and integrin αvβ6 on the surface of tumor cells. After binding to either target, JSKN022 enters the lysosome through target-mediated endocytosis. The cleavable linker is specifically hydrolyzed by proteolytic enzymes such as cathepsin B, releasing cytotoxic topoisomerase I inhibitor (T01), which then induces apoptosis of PD-L1 and/or integrin αvβ6 positive tumor cells. In addition, the inhibitor can penetrate the cell membrane and enter the antigen-negative tumor cells to exert bystander effects. These combined effects can effectively inhibit the growth of tumor cells. At present, no ADC targeting integrin αvβ6 or PD-L1 has been approved for marketing worldwide, with all related investigational candidates remaining in clinical development stages. Preclinical data demonstrate that JSKN022 exhibits potent antitumor activity in both in vitro and in vivo models against tumor cells expressing integrin αvβ6 and/or PD-L1. JSKN022 will potentially bring in novelty in the therapeutic approach for cancers that are refractory or resistant to PD-1/PD-L1 inhibitors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancer. This Phase I clinical study will evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and antitumor activity of JSKN022 in patients with advanced malignant solid tumors who have failed standard therapies, and determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). About JSKN022JSKN022 is a first-in-class ADC targeting both PD-L1 and integrin αvβ6. Based on independently developed Envafolimab, Alphamab integrates immuno-oncology (IO) mechanisms with ADC approaches. This novel drug molecule utilizes glycan-specific conjugation technology to enhance both stability and homogeneity. The topoisomerase I inhibitor T01 is site-specifically conjugated to antibodies via a cleavable linker, enhancing therapeutic efficacy. JSKN022 is expected to provide a novel therapeutic option for cancers that are refractory or resistant to PD-1/PD-L1 inhibitors. The IND application for the first-in-human clinical study of JSKN022 for the treatment of advanced malignant solid tumors has been accepted by CDE. About Alphamab OncologyAlphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. On December 12, 2019, the Company was successfully listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966. By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies. The Company has one product approved for marketing (Envafolimab, the world's first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark. Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide. View original content: SOURCE Alphamab Oncology Sign in to access your portfolio
Bloomberg
9 minutes ago
- Bloomberg
Trump Tariff Shock Poised to Deepen Rupee's Underperformance
India's rupee is poised to remain one of Asia's worst performers in the second half of the year, with US tariffs adding pressure to an already fragile economic recovery, analysts say. Analysts at Deutsche Bank AG and Barclays Plc expect the currency to drop to new record lows by the year-end amid muted foreign inflows and headwinds from US tariffs. Meanwhile, the Chinese yuan, Indonesian rupiah, Malaysian ringgit and Philippine peso are projected to gain, according to estimates compiled by Bloomberg.
Yahoo
37 minutes ago
- Yahoo
JCDecaux SE (JCDXF) (H1 2025) Earnings Call Highlights: Strong Digital Growth Amid Market Challenges
Release Date: July 31, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points JCDecaux SE (JCDXF) reported a robust revenue growth of 3.4% year-on-year in H1 2025, driven by a 12.2% increase in digital out-of-home revenue. The company achieved a significant improvement in operating margin, increasing by 17.6% with a 200 basis points improvement as a percentage of revenue. Programmatic digital out-of-home revenue saw an impressive growth of 25.2%, highlighting the company's strong digital strategy. North America was the fastest-growing region with an 11.8% increase, showing strong geographic diversification. JCDecaux SE (JCDXF) continues to lead in ESG performance, receiving high ratings from multiple agencies, which positions it well for future opportunities. Negative Points The UK market experienced a decline of 2.9% due to high comparables, impacting overall growth. China's revenue saw a mid-single-digit decline, affecting the transport segment's performance. Net income decreased compared to H1 2024, largely due to one-off factors, indicating some financial volatility. The company expects low single-digit negative organic growth for Q3 2025, influenced by tough comparables from major sporting events. Working capital requirements negatively impacted free cash flow, with timing differences expected to normalize by year-end. Q & A Highlights Warning! GuruFocus has detected 3 Warning Signs with JCDXF. Q: Can you explain the slowdown in organic sales growth compared to Q2, and do you expect a pickup in Q4? A: The slowdown is mainly due to the UK, our second-largest market, which experienced a high single-digit decline. Additionally, one-off effects from sporting events like the UEFA and Paris Olympic Games impacted growth. We don't see a slowdown in most markets globally. (Jean Charles Lecou, Co-CEO) Q: What is the impact of the digital revenue growth on your operating profit, and how do you see the digital inventory evolving over the next five years? A: Digital revenue, which constitutes 40% of our total revenue, comes from less than 10% of our inventory. In the UK, for example, digital billboards generate 90% of revenues. We expect paper billboards to disappear over the next five years, with transport and rail becoming 100% digital. (Jean Francois Decour, Chairman of the Executive Board and Co-CEO) Q: Can you provide more details on the impact of the contracts won and lost this year on 2026? A: The lost contracts in 2025 had no significant impact on our top line, representing less than 20 million annually. We expect a positive impact on the bottom line, maintaining our targets for 2026 with an operating margin above 20% and free cash flow of $300 million. (David Burg, Chief Financial IT and Operations Officer) Q: How do you view the current M&A landscape, and which regions are you most interested in? A: Our strategy remains focused on bolt-on acquisitions to reinforce our position, with Europe being a key area of interest. We are also looking at opportunities in Latin America and Asia Pacific. Our platform is unique globally, and we complement our strategy with acquisitions when it makes sense. (Jean Charles Lecou, Co-CEO) Q: What are your expectations for digital growth, and do you anticipate double-digit growth beyond 2025? A: Digital out-of-home is expected to remain the fastest-growing segment in the media business, with double-digit growth over the next couple of years. Our growth will depend on digitizing markets like France, which is currently under-penetrated. We are also accelerating digitalization in China, which will help boost growth. (Jean Francois Decour, Chairman of the Executive Board and Co-CEO) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
